Yale New Haven Hospital is thrilled to be able to offer a new multidisciplinary Neurocutaneous Syndrome Clinic (NCS) to patients aged 0 – 30 with Neurofibromatosis Type 1, Neurofibromatosis Type 2, and Tuberous Sclerosis. The clinic will include faculty with specialties in oncology, neurology, dermatology, ophthalmology, genetics, orthopedics, and neuropsychology. With FDA approval of selumetinib as well as evidence for the use of other mTOR inhibitors and MEK inhibitors in this population, we are excited to offer innovative treatments and support for our patients with Neurocutaneous Syndromes.
The clinic will be led by Dr. Asher Marks, MD, a pediatric neuro-oncologist with interest in the care of the NF population and experience with the use of cutting-edge therapeutics such as mTOR inhibitors, MEK inhibitors, and other standard cytotoxic chemotherapies.
The clinic was founded with the help of Frank Buono, PhD, an advocate for the NF community and Yale faculty member. The clinic will provide exceptional, coordinated, world class care to NCS patients regionally, and contribute to the community nationally. The multi-disciplinary team is excited to host their first clinic session on Wednesday, November 18th. For more information or to make an appointment, please call the office of Dr. Marks at (203) 785-4640.